All Clinical Trials
Search our team at AdventHealth Research Institute
-
NCT05645692
B044157 A Phase II, Randomized, Multicenter, Open-Label, Controlled Study Of R07247669 Alone Or In Combination With Tiragolumab Versus Atezolizumab In Patients With Previously Untreated Locally Advanced Or Metastatic Urothelial Bladder Cancer Who Are Ineligible For Platinum-Containing Chemotherapy
This study is not currently enrolling.Associated Conditions: Urothelial CancerResearch Area: Clinical Cancer ResearchResearch Location: Orlando, Florida -
NCT05176483
A Dose-Escalation and Expansion Study of the Safety and Efficacy of XL092 in Combination with Immuno-Oncology Agents in Subjects with Unresectable Advanced or Metastatic Solid Tumors (STELLAR-002)
This study is not currently enrolling.Associated Conditions: Multiple Tumor TypesResearch Area: Clinical Cancer ResearchResearch Location: Celebration, FloridaYou are being asked to take part in a clinical research study called STELLAR-002 because you have been diagnosed with cancer or your cancer has worsened since your last treatment. If you join this...
-
NCT05047263
FIND-CKD: A randomized, double-blind, placebo-controlled, parallel-group, multicenter Phase 3 study to investigate the efficacy and safety of FInerenone, in addition to standard of care, on the progression of kidney disease in patients with Non-Diabetic Chronic Kidney Disease.
This study is not currently enrolling.Research Area: Translational ResearchResearch Location: Orlando, FloridaStudy Purpose: To determine the safety and efficacy of Finerenone along with standard of care, on the progression of kidney disease in patients with Non-Diabetic Chronic Kidney Disease.
To be...
-
Comparative effectiveness of Juntos Después del Cáncer (JDC) among Breast Cancer Survivors and their Intimate Partners
This study is not currently enrolling.Research Area: Clinical Cancer ResearchResearch Location: Orlando, Florida -
NCT05626634
A Phase 2, multicenter, open-label, long-term safety study of LP352 in subjects with developmental and epileptic encephalopathy who completed Study LP352-201 and are candidates for continuous treatment for up to 52 weeks.
This study is not currently enrolling.Research Area: Neuroscience ResearchYou, or you and the individual you care for, are being asked to take part in a research study because you have seizures associated with developmental and epileptic encephalopathy (DEE) and you have...
-
NCT05945433
Growth and Tolerance of Preterm Infants Fed an Experimental Human Milk Fortifier
This study is not currently enrolling.Associated Conditions: NeonatalResearch Area: Clinical Cancer ResearchYou are being asked to allow your baby to take part in this research study because he/she was born prematurely. Because your baby was born early, he/she will have a human milk fortifier (HMF) added to...
-
NCT05662865
CASINO: Low-Carbohydrate Diet and SGLT2-Inhibitor to Achieve Moderate Ketosis in Healthy Volunteers
This study is not currently enrolling.Research Area: Translational ResearchResearch Location: Orlando, FloridaThe purpose of this study is to test the hypothesis that a low-carbohydrate diet combined with an SGLT2-inhibitor is sufficient to induce moderate ketosis in healthy volunteers.
To be enrolled in...
-
NCT04865770
REMODEL: Renal Mode of Action of Semaglutide in Patients with Type 2 Diabetes and Chronic Kidney Disease.
This study is not currently enrolling.Associated Conditions: Diabetes-Care DeliveryResearch Area: Translational ResearchResearch Location: Orlando, FloridaStudy Purpose: The purpose of this study is to determine how Semaglutide works in the kidneys in people with type 2 diabetes and chronic kidney disease.
To be enrolled in this study, you must meet...
-
NCT05394519
REDEFINE2: Efficacy and safety of cagrilintide s.c. 2.4 mg in combination with semaglutide s.c. 2.4 mg (CagriSema s.c. 2.4 mg/2.4 mg) once-weekly in participants with overweight or obesity and type 2 diabetes.
This study is not currently enrolling.Associated Conditions: Diabetes-Drug StudyResearch Area: Translational ResearchResearch Location: Orlando, FloridaStudy Purpose: The purpose of the study is to investigate the efficacy and safety of two medications, cagrilintide and semaglutide. Cagrilintide in combination with semaglutide is currently under...
-
NCT05364073
FURMO-002: A Phase 1b Dose Escalation and Dose Expansion Study Evaluating the Safety, Pharmacokinetics, and Antitumor Activity of Furmonertinib in Patients with Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) with Activating EGFR or HER2 Mutations, Including Exon 20 Insertion Mutations
This study is not currently enrolling.Associated Conditions: Lung CancerResearch Area: Clinical Cancer ResearchThe purpose of this study is to learn about how the study drug, furmonertinib, works in patients with NSCLC who have a mutation in the EGFR or HER2 gene and how it may help them. For patients with...
-
NCT04223752
A Phase 1, open-label, non-comparative, multicenter clinical study to evaluate the safety, tolerability, and pharmacokinetics of ceftolozane/tazobactam (MK-7625A) in pediatric participants with nosocomial pneumonia
This study is not currently enrolling.Research Area: Pediatric Research and Clinical TrialsResearch Location: Orlando, FloridaCeftolozane/tazobactam, also known as Zerbaxa, is a combination product, and is available by prescription for use in adults for the treatment of complicated urinary tract infections, including...
-
NCT04529772
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Acalabrutinib in Combination with Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R CHOP) in Subjects ≤70 Years with Previously Untreated Non-Germinal Center Diffuse Large B Cell Lymphoma
This study is not currently enrolling.Associated Conditions: LeukemiaResearch Area: Clinical Cancer ResearchResearch Location: Orlando, FloridaThis study is being done to understand whether patients with a type of DLBCL known as non-germinal center diffuse large B-cell lymphoma (non-GCB DLBCL) will benefit from the addition of acalabrutinib...